Clinical trials: Moderate to Severe Psoriasis, active
Moderate to Severe Psoriatic Arthritis
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
The purpose of this 1-year open-label extension study is to characterize the longer-term safety and tolerability of DDY391 and to assess the durability of clinical response in participants with Psoriatic Arthritis (PsA) who have…
- Trial name
- NCT07923773
- Testing
- DDY391
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis.
- Trial name
- NCT05642182
- Testing
- SFA002
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- SFA Therapeutics
Psoriasis
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
- Trial name
- NCT06701513
- Testing
- Deucravacitinib
- Where
- 48 sites in France, Switzerland
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Psoriasis (PsO)
A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults
This is a 12-week, single-arm, open-label pilot study to assess the safety and preliminary efficacy of oral roflumilast in adults with moderate-to-severe plaque psoriasis.
- Trial name
- PSOROFLU (NCT07233291)
- Testing
- Oral roflumilast
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Ahmed Ibrahim
Palmoplantar Psoriasis
A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
Palmoplantar psoriasis (PPPsO) is a type of psoriasis that affects the palms of hands and soles of the feet. It can cause red, thick, scaly patches, and it is often associated with pain and itching.
- Trial name
- NCT07752108
- Testing
- Zasocitinib
- Volunteers
- 40 people
- Sponsor
- Takeda
Plaque Psoriasis
A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany
The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year…
- Trial name
- DELPHIN (NCT06104644)
- Testing
- Deucravacitinib
- Where
- 2 sites in Germany
- Volunteers
- 550 people
- Sponsor
- Bristol-Myers Squibb
Moderate to Severe Plaque Psoriasis
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II/III operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of…
- Trial name
- NCT07432854
- Testing
- CMS-D001 50mg, CMS-D001 100mg
- Where
- 21 sites in China
- Volunteers
- 540 people
- Sponsor
- Dermavon Holdings Limited
Psoriasis
A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.
- Trial name
- NCT07150988
- Testing
- HSK44459 dose level 1, HSK44459 dose level 2
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Psoriasis
A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice
The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting.
- Trial name
- G-START (NCT07746583)
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Janssen-Cilag Kft.
Psoriasis
A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, tolerability and drug survival of guselkumab in high-dose and extended-interval versus standard-dose in Chinese participants with moderate to severe plaque psoriasis.
- Trial name
- NCT07532486
- Testing
- Guselkumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Plaque Psoriasis
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT07130604
- Testing
- D-2570
- Where
- China
- Volunteers
- 390 people
- Sponsor
- InventisBio Co., Ltd
Palmoplantar Pustulosis (PPP)
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a chronic and recurrent skin disease, mainly characterized by erythema, pustules and scales on the palms and soles, often accompanied by itching and pain, which seriously affects the quality of…
- Trial name
- NCT07503652
- Testing
- Xeligekimab Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Hospital of China Medical University
Moderate-to-severe Chronic Plaque Psoriasis
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
- Trial name
- NCT07362017
- Testing
- Ponesimod
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- Vanda Pharmaceuticals
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment…
- Trial name
- MECAP (NCT07129382)
- Testing
- CS32582 capsule（low dose）, CS32582 capsule（medium dose）, CS32582 capsule（high dose）
- Where
- 11 sites in China
- Volunteers
- 220 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Plaque Psoriasis
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06550076
- Testing
- TAK-279
- Where
- 278 sites in United States, Argentina and 18 more
- Volunteers
- 2,099 people
- Sponsor
- Takeda
Plaque Psoriasis
Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis
The aim of the study is to evaluate the efficacy and safety of netakimab compared with placebo in a pediatric population of subjects over 6 years of age with moderate to severe plaque psoriasis.
- Trial name
- PLANETA-KIDS (NCT06640517)
- Testing
- Netakimab, Adalimumab
- Where
- 14 sites in Russia
- Volunteers
- 140 people
- Sponsor
- Biocad
Plaque Psoriasis
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis.
- Trial name
- NCT07326813
- Testing
- D-2570 Tablet, BMS-986165 Tablet
- Where
- China
- Volunteers
- 477 people
- Sponsor
- InventisBio Co., Ltd
Psoriasis
A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.
- Trial name
- PROGRESS-RO (NCT07582783)
- Where
- 20 sites in Romania
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
- Trial name
- N/Z (NCT07489885)
- Testing
- D-2570 Tablet
- Where
- 20 sites in United States
- Volunteers
- 75 people
- Sponsor
- InventisBio Co., Ltd